肺癌是全球男性常见癌症,大部分肺癌患者在确诊时已属晚期。对于肺癌晚期患者来说,放疗、化疗的不良反应较大,患者无法耐受;靶向药物普遍存在耐药现象;免疫治疗受程序性死亡配体-1(programmed cell death protein 1,PD-L1)的表达限制;...肺癌是全球男性常见癌症,大部分肺癌患者在确诊时已属晚期。对于肺癌晚期患者来说,放疗、化疗的不良反应较大,患者无法耐受;靶向药物普遍存在耐药现象;免疫治疗受程序性死亡配体-1(programmed cell death protein 1,PD-L1)的表达限制;抗血管治疗的出现为晚期肺癌患者提供了更多的选择。目前,多种药物联合治疗肺癌的手段日渐成熟,抗血管药物联合化疗药物或靶向药物都取得了显著的疗效。在肺癌肿瘤生长过程中,环氧化酶-2(cyclooxygenase-2,COX-2)和血管内皮生长因子(vascular endothelial growth factor,VEGF)相互促进使肿瘤血管新生,所以,选择性COX-2抑制剂联合抗血管药物是否具有协同抗肿瘤作用,其抗肿瘤机制如何,本文将针对以上问题展开论述。展开更多
保留比率肺功能减损(preserved ratio impaired spirometry, PRISm)定义为在吸入支气管扩张剂后,FEV1/FVC ≥ 0.7,FEV1% Preserved ratio impaired spirometry (PRISm) is a heterogeneous lung disease, defined by after bronchodilat...保留比率肺功能减损(preserved ratio impaired spirometry, PRISm)定义为在吸入支气管扩张剂后,FEV1/FVC ≥ 0.7,FEV1% Preserved ratio impaired spirometry (PRISm) is a heterogeneous lung disease, defined by after bronchodilator inhalation a forced expiratory volume in one second (FEV1) that is less than 80% of the predicted value, whilst maintaining FEV1/forced vital capacity (FVC) ≥ 0.7. In recent years, although the prevalence of PRISm in the population has been confirmed by some studies, in-depth discussion and research in related fields are still insufficient. Previous studies have found that PRISm population can be caused by a variety of risk factors. And compared with those with normal lung function, the risk of progression to the COPD, the risk of cardiovascular-related mortality and all-cause mortality is significantly increased. Without timely intervention, it may gradually deteriorate to COPD. So it is very important to detect and prevent PRISm early. This review encapsulates research pertaining to PRISm, spanning its incidence, risk factors, disease characteristics, associated diseases, prognosis and treatment, aiming to understand PRISm comprehensively, and hope to provide more accurate condition assessment for PRISm patients, and promote the comprehensive rehabilitation and health management of patients.展开更多
文摘肺癌是全球男性常见癌症,大部分肺癌患者在确诊时已属晚期。对于肺癌晚期患者来说,放疗、化疗的不良反应较大,患者无法耐受;靶向药物普遍存在耐药现象;免疫治疗受程序性死亡配体-1(programmed cell death protein 1,PD-L1)的表达限制;抗血管治疗的出现为晚期肺癌患者提供了更多的选择。目前,多种药物联合治疗肺癌的手段日渐成熟,抗血管药物联合化疗药物或靶向药物都取得了显著的疗效。在肺癌肿瘤生长过程中,环氧化酶-2(cyclooxygenase-2,COX-2)和血管内皮生长因子(vascular endothelial growth factor,VEGF)相互促进使肿瘤血管新生,所以,选择性COX-2抑制剂联合抗血管药物是否具有协同抗肿瘤作用,其抗肿瘤机制如何,本文将针对以上问题展开论述。
文摘保留比率肺功能减损(preserved ratio impaired spirometry, PRISm)定义为在吸入支气管扩张剂后,FEV1/FVC ≥ 0.7,FEV1% Preserved ratio impaired spirometry (PRISm) is a heterogeneous lung disease, defined by after bronchodilator inhalation a forced expiratory volume in one second (FEV1) that is less than 80% of the predicted value, whilst maintaining FEV1/forced vital capacity (FVC) ≥ 0.7. In recent years, although the prevalence of PRISm in the population has been confirmed by some studies, in-depth discussion and research in related fields are still insufficient. Previous studies have found that PRISm population can be caused by a variety of risk factors. And compared with those with normal lung function, the risk of progression to the COPD, the risk of cardiovascular-related mortality and all-cause mortality is significantly increased. Without timely intervention, it may gradually deteriorate to COPD. So it is very important to detect and prevent PRISm early. This review encapsulates research pertaining to PRISm, spanning its incidence, risk factors, disease characteristics, associated diseases, prognosis and treatment, aiming to understand PRISm comprehensively, and hope to provide more accurate condition assessment for PRISm patients, and promote the comprehensive rehabilitation and health management of patients.
